Clinical evaluation of supplemental administration of flavoxate hydrochloride in benign prostatic hyperplasia patients with nocturia resistant to an α1-adrenoceptor blocker

Shinobu Kato, Mamoru Kusaka, Ryoichi Shiroki, Masanobu Izumitani, Haruyoshi Asano, Takahiro Ooki, Masanori Yanaoka, Kiyotaka Hoshinaga

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

We examined the effectiveness of supplemental administration of flavoxate hydrochloride in patients with benign prostatic hyperplasia (BPH) whose nocturia was not adequately relieved by an α1-adrenoceptor blocker. Fifty-two patients who had two or more nocturnal micturition after administration of tamsulosin hydrochloride or naftopidil for 4 weeks or more received 400-600 mg of flavoxate hydrochloride in addition to an α1-adrenoceptor blocker for another 8-12 weeks. With supplemental administration of flavoxate hydrochloride, significant improvement was observed in the number of nocturnal micturition, total International Prostate Sympton Score, quality of life score and BPH impact index. No significant change was observed in the voided volume, Qmax, voiding time and residual urine volume. Supplemental administration of flavoxate hydrochloride is therefore effective for the improvement of nocturia and QOL in BPH patients resistant to an α1-adrenoceptor blocker.

Original languageEnglish
Pages (from-to)173-177
Number of pages5
JournalActa Urologica Japonica
Volume54
Issue number3
Publication statusPublished - 03-2008

All Science Journal Classification (ASJC) codes

  • Urology

Fingerprint Dive into the research topics of 'Clinical evaluation of supplemental administration of flavoxate hydrochloride in benign prostatic hyperplasia patients with nocturia resistant to an α<sub>1</sub>-adrenoceptor blocker'. Together they form a unique fingerprint.

Cite this